Table of Contents

Research Articles: Therapeutics, Targets, and Development

• Research Articles: Therapeutics, Targets, and Development

  Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells

  Peter Solár, Ján Koval, Jaromír Mikeš, Ján Kleban, Zuzana Solárová, Ján Lazúr, Ingrid Hodorová, Peter Fedoročko and Arthur J. Sytkowski

  Mol Cancer Ther August 1 2008 7 (8) 2263-2271; DOI:10.1158/1535-7163.MCT-08-0483

  
  
• Research Articles: Therapeutics, Targets, and Development

  Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

  Timothy P. Padera, Angera H. Kuo, Tohru Hoshida, Shan Liao, Jennifer Lobo, Kevin R. Kozak, Dai Fukumura and Rakesh K. Jain

  Mol Cancer Ther August 1 2008 7 (8) 2272-2279; DOI:10.1158/1535-7163.MCT-08-0182

  
  
• Research Articles: Therapeutics, Targets, and Development

  Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1^−/−/Mdr1a/1b^−/− (triple-knockout) and wild-type mice

  Serena Marchetti, Nienke A. de Vries, Tessa Buckle, Maria J. Bolijn, Maria A.J. van Eijndhoven, Jos H. Beijnen, Roberto Mazzanti, Olaf van Tellingen and Jan H.M. Schellens

  Mol Cancer Ther August 1 2008 7 (8) 2280-2287; DOI:10.1158/1535-7163.MCT-07-2250

  
  
• Research Articles: Therapeutics, Targets, and Development

  Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

  Bernard M. Tijink, Toon Laeremans, Marianne Budde, Marijke Stigter-van Walsum, Torsten Dreier, Hans J. de Haard, C. René Leemans and Guus A.M.S. van Dongen

  Mol Cancer Ther August 1 2008 7 (8) 2288-2297; DOI:10.1158/1535-7163.MCT-07-2384

  
  
• Research Articles: Therapeutics, Targets, and Development

  Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells

  Hongtao Gu, Xiequn Chen, Guangxun Gao and Hongjuan Dong

  Mol Cancer Ther August 1 2008 7 (8) 2298-2307; DOI:10.1158/1535-7163.MCT-08-0186

  
  
• Research Articles: Therapeutics, Targets, and Development

  Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth

  Jacqueline Sayyah, Andrew Magis, David A. Ostrov, Robert W. Allan, Raul C. Braylan and Peter P. Sayeski

  Mol Cancer Ther August 1 2008 7 (8) 2308-2318; DOI:10.1158/1535-7163.MCT-08-0279

  
  
• Research Articles: Therapeutics, Targets, and Development

  Elesclomol induces cancer cell apoptosis through oxidative stress

  Jessica R. Kirshner, Suqin He, Vishwasenani Balasubramanyam, Jane Kepros, Chin-Yu Yang, Mei Zhang, Zhenjian Du, James Barsoum and John Bertin

  Mol Cancer Ther August 1 2008 7 (8) 2319-2327; DOI:10.1158/1535-7163.MCT-08-0298

  
  
• Research Articles: Therapeutics, Targets, and Development

  Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms

  Sharmila Shankar, Qinghe Chen, Suthakar Ganapathy, Karan P. Singh and Rakesh K. Srivastava

  Mol Cancer Ther August 1 2008 7 (8) 2328-2338; DOI:10.1158/1535-7163.MCT-08-0216

  
  
• Research Articles: Therapeutics, Targets, and Development

  BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis

  Justin L. Mott, Steve F. Bronk, Ruben A. Mesa, Scott H. Kaufmann and Gregory J. Gores

  Mol Cancer Ther August 1 2008 7 (8) 2339-2347; DOI:10.1158/1535-7163.MCT-08-0285

  
  
• Research Articles: Therapeutics, Targets, and Development

  Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer

  Tadas Vasaitis, Aashvini Belosay, Adam Schayowitz, Aakanksha Khandelwal, Pankaj Chopra, Lalji K. Gediya, Zhiyong Guo, Hong-Bin Fang, Vincent C.O. Njar and Angela M.H. Brodie

  Mol Cancer Ther August 1 2008 7 (8) 2348-2357; DOI:10.1158/1535-7163.MCT-08-0230

  
  
• Research Articles: Therapeutics, Targets, and Development

  Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines

  Magdalena Zajac, Maria Victoria Moneo, Amancio Carnero, Javier Benitez and Beatriz Martínez-Delgado

  Mol Cancer Ther August 1 2008 7 (8) 2358-2366; DOI:10.1158/1535-7163.MCT-08-0327

  
  
• Research Articles: Therapeutics, Targets, and Development

  SN52, a novel nuclear factor-κB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation

  Yong Xu, Fang Fang, Daret K. St. Clair, Pradoldej Sompol, Sajni Josson and William H. St. Clair

  Mol Cancer Ther August 1 2008 7 (8) 2367-2376; DOI:10.1158/1535-7163.MCT-08-0238

  
  
• Research Articles: Therapeutics, Targets, and Development

  Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer

  Zhenfeng Duan, Edward J. Weinstein, Diana Ji, Rachel Y. Ames, Edwin Choy, Henry Mankin and Francis J. Hornicek

  Mol Cancer Ther August 1 2008 7 (8) 2377-2385; DOI:10.1158/1535-7163.MCT-08-0316

  
  
• Research Articles: Therapeutics, Targets, and Development

  Jadomycin B, an Aurora-B kinase inhibitor discovered through virtual screening

  Da-Hua Fu, Wei Jiang, Jian-Ting Zheng, Gui-Yu Zhao, Yan Li, Hong Yi, Zhuo-Rong Li, Jian-Dong Jiang, Ke-Qian Yang, Yanchang Wang and Shu-Yi Si

  Mol Cancer Ther August 1 2008 7 (8) 2386-2393; DOI:10.1158/1535-7163.MCT-08-0035

  
  
• Research Articles: Therapeutics, Targets, and Development

  Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

  Alessandra Blasina, Jill Hallin, Enhong Chen, Maria Elena Arango, Eugenia Kraynov, James Register, Stephan Grant, Sacha Ninkovic, Ping Chen, Tim Nichols, Patrick O'Connor and Kenna Anderes

  Mol Cancer Ther August 1 2008 7 (8) 2394-2404; DOI:10.1158/1535-7163.MCT-07-2391

  
  
• Research Articles: Therapeutics, Targets, and Development

  The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma

  Szu-Chieh Mei and Rong-Tsun Wu

  Mol Cancer Ther August 1 2008 7 (8) 2405-2414; DOI:10.1158/1535-7163.MCT-07-2398

  
  
• Research Articles: Therapeutics, Targets, and Development

  New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine

  Stephan A. Veltkamp, Dick Pluim, Maria A.J. van Eijndhoven, Maria J. Bolijn, Felix H.G. Ong, Rajgopal Govindarajan, Jashvant D. Unadkat, Jos H. Beijnen and Jan H.M. Schellens

  Mol Cancer Ther August 1 2008 7 (8) 2415-2425; DOI:10.1158/1535-7163.MCT-08-0137

  
  
• Research Articles: Therapeutics, Targets, and Development

  IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents

  Anne-Marie Liberatore, Hélène Coulomb, Dominique Pons, Olivier Dutruel, Philip G. Kasprzyk, Mark Carlson, Ann Savola Nelson, Simon P. Newman, Chloe Stengel, Pierrïck Auvray, Vincent Hesry, Béatrice Foll, Nadine Narboux, Delphine Morlais, Mélissa Le Moing, Sonia Bernetiere, Raphael Dellile, Jose Camara, Eric Ferrandis, Dennis C. Bigg and Grégoire P. Prévost

  Mol Cancer Ther August 1 2008 7 (8) 2426-2434; DOI:10.1158/1535-7163.MCT-08-0208

  
  
• Research Articles: Therapeutics, Targets, and Development

  Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography

  L.W. Lawrence Woo, Delphine S. Fischer, Christopher M. Sharland, Melanie Trusselle, Paul A. Foster, Surinder K. Chander, Anna Di Fiore, Claudiu T. Supuran, Giuseppina De Simone, Atul Purohit, Michael J. Reed and Barry V.L. Potter

  Mol Cancer Ther August 1 2008 7 (8) 2435-2444; DOI:10.1158/1535-7163.MCT-08-0195

  
  
• Research Articles: Therapeutics, Targets, and Development

  Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2

  Jirouta Kitagaki, Keli K. Agama, Yves Pommier, Yili Yang and Allan M. Weissman

  Mol Cancer Ther August 1 2008 7 (8) 2445-2454; DOI:10.1158/1535-7163.MCT-08-0063

  
  
• Research Articles: Therapeutics, Targets, and Development

  High-content imaging characterization of cell cycle therapeutics through in vitro and in vivo subpopulation analysis

  Jonathan Low, Shuguang Huang, Wayne Blosser, Michele Dowless, John Burch, Blake Neubauer and Louis Stancato

  Mol Cancer Ther August 1 2008 7 (8) 2455-2463; DOI:10.1158/1535-7163.MCT-08-0328

  
  
• Research Articles: Therapeutics, Targets, and Development

  Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer

  Ute Distler, Jamal Souady, Marcel Hülsewig, Irena Drmić-Hofman, Jörg Haier, Axel Denz, Robert Grützmann, Christian Pilarsky, Norbert Senninger, Klaus Dreisewerd, Stefan Berkenkamp, M. Alexander Schmidt, Jasna Peter-Katalinić and Johannes Müthing

  Mol Cancer Ther August 1 2008 7 (8) 2464-2475; DOI:10.1158/1535-7163.MCT-08-0353

  
  
• Research Articles: Therapeutics, Targets, and Development

  Autophagy inhibition enhances anthocyanin-induced apoptosis in hepatocellular carcinoma

  Luigia Longo, Francesca Platini, Anna Scardino, Oscar Alabiso, Giuseppe Vasapollo and Luciana Tessitore

  Mol Cancer Ther August 1 2008 7 (8) 2476-2485; DOI:10.1158/1535-7163.MCT-08-0361

  
  
• Research Articles: Therapeutics, Targets, and Development

  Anti-CD30 diabody-drug conjugates with potent antitumor activity

  Kristine M. Kim, Charlotte F. McDonagh, Lori Westendorf, Lindsay L. Brown, Django Sussman, Tiffany Feist, Robert Lyon, Stephen C. Alley, Nicole M. Okeley, Xinqun Zhang, Melissa C. Thompson, Ivan Stone, Hans-Peter Gerber and Paul J. Carter

  Mol Cancer Ther August 1 2008 7 (8) 2486-2497; DOI:10.1158/1535-7163.MCT-08-0388

  
  
• Research Articles: Therapeutics, Targets, and Development

  Human colorectal tumors and metastases express Gb₃ and can be targeted by an intestinal pathogen-based delivery tool

  Thomas Falguières, Matthias Maak, Claus von Weyhern, Marianne Sarr, Xavier Sastre, Marie-France Poupon, Sylvie Robine, Ludger Johannes and Klaus-Peter Janssen

  Mol Cancer Ther August 1 2008 7 (8) 2498-2508; DOI:10.1158/1535-7163.MCT-08-0430

  
  
• Research Articles: Therapeutics, Targets, and Development

  Cellular commitment to reentry into the cell cycle after stalled DNA is determined by site-specific phosphorylation of Chk1 and PTEN

  Sarah A. Martin and Toru Ouchi

  Mol Cancer Ther August 1 2008 7 (8) 2509-2516; DOI:10.1158/1535-7163.MCT-08-0199

  
  
• Research Articles: Therapeutics, Targets, and Development

  Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells

  John O. Richards, Sher Karki, Greg A. Lazar, Hsing Chen, Wei Dang and John R. Desjarlais

  Mol Cancer Ther August 1 2008 7 (8) 2517-2527; DOI:10.1158/1535-7163.MCT-08-0201

  
  
• Research Articles: Therapeutics, Targets, and Development

  Adenoviral endoplasmic reticulum–targeted mda-7/interleukin-24 vector enhances human cancer cell killing

  Abujiang Pataer, Wenxian Hu, Lu Xiaolin, Sunil Chada, Jack A. Roth, Kelly K. Hunt and Stephen G. Swisher

  Mol Cancer Ther August 1 2008 7 (8) 2528-2535; DOI:10.1158/1535-7163.MCT-08-0083

  
  
• Research Articles: Therapeutics, Targets, and Development

  Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248

  Rebecca G. Bagley, Cecile Rouleau, Thia St. Martin, Paula Boutin, William Weber, Melanie Ruzek, Nakayuki Honma, Mariana Nacht, Srinivas Shankara, Shiro Kataoka, Isao Ishida, Bruce L. Roberts and Beverly A. Teicher

  Mol Cancer Ther August 1 2008 7 (8) 2536-2546; DOI:10.1158/1535-7163.MCT-08-0050

  
  
• Research Articles: Therapeutics, Targets, and Development

  Tumor necrosis factor-α–induced accentuation in cryoinjury: mechanisms in vitro and in vivo

  Jing Jiang, Raghav Goel, M. Arif Iftekhar, Rachana Visaria, John D. Belcher, Gregory M. Vercellotti and John C. Bischof

  Mol Cancer Ther August 1 2008 7 (8) 2547-2555; DOI:10.1158/1535-7163.MCT-07-2421

  
  
• Research Articles: Therapeutics, Targets, and Development

  Fatty acid synthase inhibition results in a magnetic resonance–detectable drop in phosphocholine

  James Ross, Amer M. Najjar, Madhuri Sankaranarayanapillai, William P. Tong, Kumaralal Kaluarachchi and Sabrina M. Ronen

  Mol Cancer Ther August 1 2008 7 (8) 2556-2565; DOI:10.1158/1535-7163.MCT-08-0015

  
  
• Research Articles: Therapeutics, Targets, and Development

  Relaxin treatment of solid tumors: effects on electric field–mediated gene delivery

  Joshua Henshaw, Brian Mossop and Fan Yuan

  Mol Cancer Ther August 1 2008 7 (8) 2566-2573; DOI:10.1158/1535-7163.MCT-08-0435